Self-Adjuvanted Nanoparticles as an HIV Vaccine Platform

作为 HIV 疫苗平台的自佐纳米颗粒

• 批准号: 376546
• 负责人: Sicard Taylor
• 金额: $ 10.93万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-11-01 至 2020-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=376546&lang=en
• 关键词: B Cells; Hiv; Protein Engineering; Self-Assembling Nanoparticles; Vaccines

Over the past 25 years, efforts have failed to develop a vaccine capable of broadly protecting against HIV. In response to HIV, the human immune system seems generally unable to respond effectively, providing limited protection to the infected individual.

在过去的25年中，努力未能开发出能够广泛保护艾滋病毒的疫苗。为了回应艾滋病毒，人类免疫系统似乎通常无法有效反应，从而为受感染的人提供了有限的保护。